Akers Biosciences Updates on Akers Wellness(TM) Tests
April 24 2017 - 7:00AM
Marketwired
Akers Biosciences Updates on Akers Wellness(TM) Tests
Akers Wellness iOS digital application approved by the Apple App
Store
THOROFARE, NJ-(Marketwired - Apr 24, 2017) - Akers Biosciences,
Inc. (NASDAQ: AKER) (AIM: AKR.L) ("Akers Bio" or the "Company"), a
developer of rapid health information technologies, announces that
the Akers Wellness™ app, which enables users to track the results
of Akers Wellness™ breath-based tests via their mobile device, has
been approved by the Apple App Store and is now available for
download on iOS devices. The Akers Wellness™ app has until now only
been available for android devices on the Google Play Store.
The app works in conjunction with BreathScan Lync™, the new
bluetooth-enabled reading device from Akers Wellness™, and
disposable breath-based test cartridges, to help promote, track
and/or encourage choices related to general health and
wellbeing.
The iOS compatibility is a significant step in the
commercialization of Akers Wellness™ tests due to the dominance of
iOS devices in the mobile device market. A key target in the
Company's marketing strategy is the multilevel marketing
nutraceutical suppliers. The Company believes iOS compatibility is
critical to the success in this market and will now rapidly proceed
to market to this industry.
The first commercialized Akers Wellness™ breath test is
BreathScan OxiChek™, the first disposable breath test to rapidly
determine levels of oxidative stress in the body by measuring the
levels of certain abundant free radicals. Unlike current laboratory
testing methods that test only a few free radicals using an
invasive blood draw - and have a turnaround time of 7 to 10 days -
Akers Bio's rapid OxiChek™ test detects a broad spectrum of free
radicals contained in a person's exhaled breath in just a few
minutes. Frequent use of OxiChek™ may help health practitioners to
monitor and adjust their clients' regimen of nutritional
supplementation in order to manage oxidative stress - an indicator
of the overall health and wellbeing of a person.
A highly successful clinical trial of OxiChek™ carried out in
2016 demonstrated a correlation between OxiChek™ and the standard
reference laboratory blood testing method (TBARS) of 99.5%.
OxiChek™ is now commercialized and selling through the Company's
distributor, Aero-Med, to anti-aging, functional and integrative
health and wellness treatment practitioners in the US. The Company
is also ramping up marketing initiatives of OxiChek™ to
professionals through enhanced e-commerce and social media
platforms.
In addition to targeting professionals, Akers Wellness™ intends
to start marketing OxiChek™ through direct-to-consumer channels
this year. This will include a television marketing campaign
through the popular Balancing Act national television show
on the Lifetime network. Balancing Act is America's
premier morning show that introduces positive solutions to busy,
on-the-go modern women. Akers Wellness™ has completed filming of
the program, which will be aired multiple times on Lifetime
this quarter and syndicated to approximately 200 affiliates. This
marketing initiative is targeting women aged 25-45 and will
potentially reach approximately 98 million households and thousands
of online viewers.
Raymond F. Akers, Jr. PhD, Vice Chairman of Akers Bio,
commented: "We have completed our near-term product offering for
the expansive health and wellness and anti-aging industry with the
addition of iOS compatibility for the Akers Wellness™ app, which
was the last hurdle to what we believe will be a rapid growth curve
in revenue for these products. Akers Wellness™ is dedicated to
improving the health and wellbeing of its customers and we believe
that OxiChek™ will have a significant impact on this goal. We are
turning our attention to providing more services to our customers
through our app and, in turn, creating secondary revenue generating
opportunities. The Company is pleased to be launching enhanced
e-commerce and social media platforms around OxiChek™ and is
looking forward to the start of our television marketing campaign
in the coming weeks."
John J. Gormally, Chief Executive Officer of Akers Bio, added:
"I am very excited about the advancements in our commercialization
strategy for Akers Wellness™ products and look forward to these
propelling our sales, initially of OxiChek™, and later our other
Akers Wellness™ tests."
About Akers Biosciences, Inc. Akers Bio develops, manufactures,
and supplies rapid screening and testing products designed to
deliver quicker and more cost-effective healthcare information to
healthcare providers and consumers. The Company has advanced the
science of diagnostics while responding to major shifts in
healthcare through the development of several proprietary platform
technologies. The Company's state-of-the-art rapid diagnostic
assays can be performed virtually anywhere in minutes when time is
of the essence. The Company has aligned with major healthcare
companies and high volume medical product distributors to maximize
product offerings, and to be a major worldwide competitor in
diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information: Akers Biosciences, Inc. John J. Gormally
Chief Executive Officer Raymond F. Akers, Jr. PhD, Vice Chairman
Tel. +1 856 848 8698 Taglich Brothers, Inc. (Investor Relations)
Chris Schreiber Tel. +1 917 445 6207 Email: cs@taglichbrothers.com
Vigo Communications (Global Public Relations) Ben Simons Fiona
Henson Tel. +44 (0)20 7830 9700 Email: akers@vigocomms.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Apr 2023 to Apr 2024